In a significant development, Bharat Biotech's COVID-19 vaccine, Covaxin, got DGCI's approval for usage on kids aged 2-18.
Context
In a significant development, Bharat Biotech's COVID-19 vaccine, Covaxin, got DGCI's approval for usage on kids aged 2-18.
Key-points
- Covaxin, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
- The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.
- The vaccine is developed using Whole-Virion Inactivated Vero Cellderived platform technology.
- Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects.
- They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.
- The World Health Organization (WHO) is yet to grant emergency use authorisation to Covaxin.
Bharat Biotech based in Hyderabad
- Bharat Biotech Indian biotechnology is based in Hyderabad,
- Bharat Biotech International Limited specializes in drug discovery, drug development, vaccine production, bio-therapeutics, pharmaceuticals, and health care products.
|
